7Baggers
Quarterly
Annual
    Unit: USD2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-02-14 2009-02-14 2007-02-14 
      
    		                                                           
      cash flows from operating activities:
    		                                                           
      net income
    		7,985,000 668,000 13,158,000 7,422,000 11,550,000 -2,014,000 10,630,000 1,401,000 1,721,000 -5,265,000 -9,795,000 -17,947,000 -14,432,000 -29,023,000 -25,998,000 -28,061,000 -4,426,000 -35,523,000 -12,916,000 -26,411,000 -11,255,000 -10,252,000 -9,322,000 -14,263,000 -10,370,000 -12,387,000 -14,883,000 -9,751,000 -24,164,000 -22,675,000 -30,385,000 -32,784,000 -32,886,000 -35,339,000 -16,324,000 53,974,000 126,521,000 -29,958,000 -24,873,000 -277,019,000 -31,857,000 -28,911,000 -30,658,000 -36,441,000 -36,519,000 -73,366,000 -52,056,000 -53,583,000 -50,818,000 -46,124,000 -40,965,000 -51,781,000 -42,834,000 -36,578,000 -38,173,000 -36,397,000 -41,525,000 -59,412,000 -119,867,000 
      adjustments to reconcile net income to net cash from operating activities:
    		                                                           
      stock-based compensation
    		4,318,000 7,520,000 5,385,000 5,818,000 5,227,000 6,428,000 3,885,000                                                     
      interest on liability for sale of future royalties
    		3,512,000 3,475,000 3,577,000 3,452,000 4,089,000 4,383,000 4,248,000                                                     
      sold portion of royalty revenue
    		-3,332,000 -3,123,000 -3,000,000 -2,701,000 -2,709,000                                                       
      write-off of inventory
    		3,277,000 4,592,000 466,000 1,946,000 291,000 589,000 1,029,000 915,000 300,000 943,000 2,416,000 834,000 917,000       0 0 0 496,000     420,000 1,013,000 177,000 602,000                             
      depreciation and amortization
    		2,061,000 2,087,000 2,106,000 2,160,000 2,119,000 1,731,000 1,361,000 1,225,000 1,137,000 1,115,000 1,058,000  1,769,000 1,411,000 1,324,000                                       3,647,000 3,696,000 3,815,000 4,119,000 4,515,000 2,138,000 
      loss on foreign currency transaction
    		                                                           
      impairment loss on available-for-sale investment
    		                                                           
      net accretion of investments
    		-567,000 -759,000 -919,000  -1,656,000 -1,125,000 -984,000                                                     
      amortization of right-of-use assets
    		740,000 531,000 544,000 528,000 493,000 319,000 328,000 323,000 321,000 319,000 338,000 332,000 324,000 2,042,000 289,000 753,000 -163,000 359,000 309,000 298,000 303,000 294,000 282,000 279,000 285,000 223,000 395,000                                 
      amortization of debt discount and issuance costs
    		158,000 109,000 109,000 313,000 417,000 415,000 501,000 515,000 629,000 472,000 469,000                                                 
      loss on settlement of debt
    		                                                           
      gain on bargain purchase
    		   0                                                        
      loss on estimated returns of acquired product
    		   0 0 275,000 1,169,000                                                     
      interest on mann group convertible note
    		   0 0 1,000 55,000                                                     
      other
    		   -290,000 0 0 49,000 94,000 -188,000 -295,000 50,000         0 0 0 19,000 4,000   -1,000 -131,000 0 -4,000 110,000 -147,000 133,000   -698,000 0 21,000 696,000 45,000 1,000 1,000 -7,000 -3,000    5,000 -1,000 0 -2,000 2,000 3,000 -8,000 1,000  5,000   
      changes in operating assets and liabilities:
    		                                                           
      accounts receivable
    		9,759,000 1,758,000 -17,096,000 6,380,000 5,162,000 -3,434,000 -5,456,000 7,366,000 5,967,000 -8,075,000 -2,913,000 6,692,000 -8,463,000 -5,207,000 -4,829,000 4,451,000 -3,140,000 -2,732,000 645,000 -83,000 -769,000 1,808,000 -1,661,000 580,000 881,000 -1,215,000 258,000 -1,265,000 96,000 -1,298,000 1,128,000 -985,000 -492,000 -874,000 -136,000 2,812,000                        
      inventory
    		-1,758,000 -4,191,000 -1,472,000 -3,169,000 -2,201,000 1,100,000 1,074,000 -2,343,000 -2,127,000 -4,236,000 -2,641,000 -4,333,000 1,383,000 -1,828,000 -892,000 -1,572,000 0 -2,432,000 -77,000 -92,000 -1,058,000 -592,000 428,000 -463,000 271,000 -243,000 -123,000 -1,232,000 -122,000 38,000 -1,836,000 -2,499,000 43,000 526,000 -1,367,000 2,793,000 -2,258,000   -12,702,000 -3,586,000 -3,027,000 -7,119,000                 
      prepaid expenses and other current assets
    		-6,989,000 -2,327,000 -3,044,000 -132,000 -1,148,000 -2,020,000 -3,274,000 -905,000 -3,285,000 -7,657,000 2,426,000 -7,465,000 -7,852,000 235,000 -470,000 -255,000 397,000 -858,000 356,000 1,152,000 -2,658,000 364,000 988,000 695,000 -878,000 -314,000 164,000 459,000 -445,000 -216,000 656,000 51,000 -497,000 944,000 856,000 170,000 -3,111,000 1,384,000 1,211,000 6,506,000 849,000 2,299,000 3,831,000 47,000 -16,557,000 -56,000 1,845,000 -257,000 -2,045,000 647,000 690,000 16,462,000 -2,276,000 -16,096,000 365,000 335,000 370,000 1,076,000 2,682,000 
      other assets
    		-1,000 136,000 -1,661,000 -749,000 -612,000 -1,895,000 -314,000 298,000 -15,000   1,091,000 -127,000 -121,000 -320,000 301,000 -237,000 -105,000 -97,000 36,000 109,000 42,000 40,000     0 121,000 41,000 38,000 22,000 41,000 86,000 39,000 54,000 545,000 -152,000 -86,000 822,000 194,000 6,000 -872,000 -485,000 1,000           0 87,000  -182,000 
      accounts payable
    		-2,988,000 5,216,000 -1,751,000 348,000 -3,112,000 2,407,000 -2,431,000 -7,175,000 -373,000 3,238,000 2,837,000 1,180,000 2,049,000 -878,000 1,745,000 -2,572,000 2,042,000 780,000 1,124,000 -215,000 -24,000 -910,000 1,942,000 -6,875,000 4,128,000 555,000 1,599,000 -436,000 -3,422,000 4,261,000 -2,008,000 1,701,000 -1,258,000 5,022,000 -1,665,000 -1,830,000 2,244,000 2,267,000 -14,799,000 11,111,000 -462,000 1,946,000 -4,182,000 -10,070,000 12,125,000 2,605,000 -1,038,000 858,000 -955,000 -50,000 -924,000 1,570,000 -2,770,000 2,957,000 -1,713,000 2,793,000 -218,000 -3,194,000 15,636,000 
      accrued expenses and other current liabilities
    		-761,000 -9,467,000 134,000 2,106,000 -3,046,000 -2,433,000 670,000 10,430,000 579,000 1,572,000 -5,975,000 2,212,000 -2,801,000 -644,000 510,000 5,343,000 256,000 -5,073,000 8,288,000 2,705,000 1,984,000 -3,223,000 1,880,000 3,632,000 -594,000 -1,876,000 2,336,000 1,689,000 -258,000 -1,857,000 2,675,000 43,000 3,372,000 -1,560,000 1,077,000 -6,227,000 3,912,000 2,175,000 488,000 -6,545,000 1,878,000 2,860,000 -10,660,000 5,279,000 312,000 3,389,000 -6,704,000 150,000 1,127,000 1,683,000 715,000 -21,823,000 3,590,000 31,420,000 1,888,000 5,184,000 3,850,000 -10,803,000 -8,371,000 
      deferred revenue
    		1,891,000 -2,691,000 -4,450,000 -8,101,000 -1,868,000 -1,806,000 -3,537,000 5,740,000 9,402,000 15,762,000 8,558,000 5,635,000 2,353,000 4,006,000 7,053,000 4,802,000 -6,147,000 -5,791,000 -7,431,000 4,371,000 -6,478,000 4,432,000 -8,235,000 6,004,000 -5,926,000 -7,481,000 686,000     17,000    1,405,000                        
      recognized loss on purchase commitments
    		   -1,000 1,000 -2,021,000 -669,000 -2,614,000 -2,524,000 -2,212,000 -2,074,000 -1,403,000 -1,378,000 -1,426,000 -1,502,000 -920,000 -1,336,000 -1,257,000 -2,379,000 -3,516,000 1,000   0 -411,000 -2,021,000 -1,963,000  -365,000 -5,653,000 -147,000 -4,097,000 -148,000 34,000 -534,000 38,199,000                        
      operating lease liabilities
    		46,000 53,000 -972,000 -885,000 -861,000 -314,000 -232,000 -607,000 -625,000 -467,000 -686,000 -324,000 -544,000 -1,869,000 -572,000 -768,000 187,000 -1,221,000 -333,000 775,000 -686,000 -677,000 -724,000 -608,000                                    
      net cash from operating activities
    		23,640,000 8,950,000 -6,377,000 22,644,000 9,331,000 3,833,000 6,703,000 21,678,000 8,664,000 2,596,000 1,156,000 -2,376,000 -28,073,000 -31,982,000 -18,248,000 -12,347,000 -15,184,000 -21,447,000 -12,731,000 235,000 -13,460,000 -3,684,000 -11,219,000 -5,107,000 -52,051,000 -19,728,000 -11,597,000 24,988,000 -13,919,000 -27,150,000 -21,650,000 -29,981,000 -23,270,000 -20,034,000 8,507,000 -12,752,000 -23,071,000 -11,509,000 -30,758,000 -22,551,000 -19,892,000 -17,809,000 3,020,000 -35,744,000 100,238,000 -23,418,000 -36,990,000 -34,051,000 -32,910,000 -29,744,000 -32,027,000 -28,098,000 -34,258,000 -25,018,000 -32,486,000 -20,355,000 -30,704,000 -60,669,000 -102,992,000 
      capex
    		-1,125,000 -1,117,000 -330,000 -2,896,000 -1,417,000 -2,972,000 -2,408,000 -5,874,000 -11,387,000 -16,869,000 -8,311,000 -5,096,000 -271,000 2,834,000 -5,056,000 -5,190,000 -4,246,000 -1,054,000 -976,000 -497,000 -4,000 -150,000 -150,000 -109,000 -963,000 -1,224,000 -269,000 0 0 0 0 0 0 0 0 0 0 0 -1,144,000 -316,000 -1,232,000 -4,534,000 -4,203,000 -4,963,000 -9,467,000 -8,258,000 -1,409,000 -6,166,000 -230,000 -132,000 -1,459,000 -65,000 -124,000 -125,000 -323,000 -155,000 -1,993,000 -5,622,000 -34,799,000 
      free cash flows
    		22,515,000 7,833,000 -6,707,000 19,748,000 7,914,000 861,000 4,295,000 15,804,000 -2,723,000 -14,273,000 -7,155,000 -7,472,000 -28,344,000 -29,148,000 -23,304,000 -17,537,000 -19,430,000 -22,501,000 -13,707,000 -262,000 -13,464,000 -3,834,000 -11,369,000 -5,216,000 -53,014,000 -20,952,000 -11,866,000 24,988,000 -13,919,000 -27,150,000 -21,650,000 -29,981,000 -23,270,000 -20,034,000 8,507,000 -12,752,000 -23,071,000 -11,509,000 -31,902,000 -22,867,000 -21,124,000 -22,343,000 -1,183,000 -40,707,000 90,771,000 -31,676,000 -38,399,000 -40,217,000 -33,140,000 -29,876,000 -33,486,000 -28,163,000 -34,382,000 -25,143,000 -32,809,000 -20,510,000 -32,697,000 -66,291,000 -137,791,000 
      cash flows from investing activities:
    		                                                           
      purchase of available-for-sale securities
    		-55,953,000 -44,023,000 -44,104,000         0 0 0 -5,000,000 0 0                                           
      proceeds from maturities of available-for-sale securities
    		42,020,000 51,396,000 50,396,000                                                         
      issuance of note receivable
    		                                                           
      purchase of property and equipment
    		-1,125,000 -1,117,000 -330,000 -2,896,000 -1,417,000 -2,972,000 -2,408,000 -5,874,000 -11,387,000 -16,869,000 -8,311,000 -5,096,000 -271,000 2,834,000 -5,056,000 -5,190,000 -4,246,000 -1,054,000 -976,000 -497,000 -4,000 -150,000 -150,000 -109,000 -963,000 -1,224,000 -269,000         0 0 0 -1,144,000 -316,000 -1,232,000 -4,534,000 -4,203,000 -4,963,000 -9,467,000 -8,258,000 -1,409,000 -6,166,000 -230,000 -132,000 -1,459,000 -65,000 -124,000 -125,000 -323,000 -155,000 -1,993,000 -5,622,000 -34,799,000 
      purchase of held-to-maturity securities
    		                                                           
      proceeds from maturities of held-to-maturity securities
    		                                                           
      proceeds from insurance claim
    		   0 0 0 396,000 0                                                    
      net cash from investing activities
    		-25,058,000 6,256,000 5,962,000 48,224,000 -41,256,000 -55,180,000 -48,437,000 -7,895,000 -11,549,000 3,664,000 13,792,000 15,010,000 27,348,000 2,022,000 -39,506,000 -12,579,000 4,992,000 -112,532,000 -31,418,000 -4,480,000 -4,000 -150,000 19,850,000 -202,000 3,761,000 -1,369,000 -25,033,000 -244,000    0 0 24,000 16,651,000 0 0 0 -1,127,000 -312,000 -1,154,000 -4,534,000 -4,203,000 -14,213,000 -217,000 -8,258,000 -1,409,000 -6,166,000 -230,000 -132,000 -1,459,000 -61,000 -124,000 -84,000 -291,000 -125,000 1,835,000 178,000 -35,382,000 
      cash flows from financing activities:
    		                                                           
      proceeds from term loan
    		                                                           
      payment of loan issuance costs
    		                                                           
      payments for taxes related to net issuance of common stock associated with restricted stock units and stock options
    		-743,000 -5,983,000 1,590,000 91,000 -1,511,000 -4,933,000 266,000 38,000 -1,708,000                                                   
      principal payments on financing liability
    		-154,000 -176,000 -200,000 -116,000 -79,000                                                       
      proceeds from market price stock purchase plan and employee stock purchase plan
    		50,000   819,000 0   745,000 0                                                   
      milestone right agreement payment
    		                                                           
      principal payments on financing lease liability
    		    0                                                       
      principal and early extinguishment payments on midcap credit facility
    		   0 0                                                       
      principal and early extinguishment payments on mann group convertible note
    		   0 0                                                       
      net cash from financing activities
    		71,806,000 -5,510,000 1,390,000 -86,900,000 -2,342,000 -44,550,000 -3,474,000 141,681,000 -283,000 -5,945,000 1,154,000 2,825,000 19,526,000 -1,776,000 813,000 97,370,000 -590,000 -51,490,000 224,977,000 18,694,000 2,640,000 28,188,000 331,000    3,000 35,967,000 -1,823,000 26,622,000 528,000 58,244,000 -22,000 15,416,000 -75,000 117,000 -5,132,000 47,589,000 464,000 49,009,000 -53,213,000 8,686,000 1,186,000 -1,667,000 31,230,000 37,131,000 3,368,000 17,204,000 98,414,000 30,400,000 -349,000 88,234,000 91,259,000 -86,365,000 86,451,000 375,000 9,720,000 59,957,000 98,000 
      net increase in cash, cash equivalents and restricted cash
    		70,388,000 9,696,000 975,000 -16,032,000 -34,267,000                                                       
      cash, cash equivalents and restricted cash, beginning of period
    		0 0 47,076,000 0 0                                                       
      cash, cash equivalents and restricted cash, end of period
    		70,388,000 9,696,000 48,051,000 -16,032,000 -34,267,000                                                       
      gain on foreign currency transaction
    		 5,363,000 2,509,000      -2,065,000 251,000 954,000                                                 
      loss on available-for-sale securities
    		                                                   0 0 0 117,000     
      milestone payment
    		   0    0    0    0 0                       0 1,000 0 -4,220,000                 
      supplemental cash flows disclosures:
    		                                                           
      interest paid in cash
    		  3,012,000          802,000 741,000 3,600,000                                          5,504,000 12,000  
      income taxes paid in cash
    		  207,000                                                         
      non-cash investing and financing activities:
    		                                                           
      non-cash construction-in-progress, property and equipment
    		  144,000                                                         
      loss on disposal of fixed assets
    		                                                           
      net amortization of investments
    		                                                           
      (gain) loss on foreign currency transaction
    		     -529,000 -1,399,000                                                     
      interest accretion on financing liability
    		                                                           
      deposits from customer
    		               -57,000 -310,000                                           
      acquisition of v-go
    		           -242,000 0                                               
      proceeds from sale of future royalties
    		                                                           
      issuance costs associated with sale of future royalties
    		                                                           
      principal and early extinguishment payments on senior convertible notes
    		                                                           
      proceeds from at-the-market offering
    		                0 0 1,886,000    668,000                                     
      issuance costs associated with at-the-market offering
    		       0 -67,000 -17,000 -24,000      0 0 -38,000    -20,000                                     
      loss on extinguishment of debt
    		    0           0 -4,930,000            712,000 -772,000 825,000  0       0                    
      gain on available-for-sale securities
    		        0                                                   
      purchase of held-to-maturity debt securities
    		    -86,342,000 -119,048,000 -68,399,000 -28,579,000 -24,069,000                                                   
      proceeds from held-to-maturity debt securities
    		    46,503,000 66,840,000 21,974,000                                                     
      proceeds from at-the-market-offering
    		       0 4,105,000 1,584,000 1,198,000                                                 
      proceeds from market price stock purchase plan
    		      1,361,000      0 0 684,000     201,000 0       95,000                                
      principal payment on financing liability
    		      -101,000                                                     
      principal payment on midcap credit facility
    		      -5,000,000                                                     
      net increase in cash and cash equivalents
    		      -45,208,000 155,464,000 -3,168,000 315,000 16,102,000  18,801,000                     -4,594,000 25,083,000   36,080,000 -31,421,000 26,146,000 -74,259,000 -13,657,000 3,000 -51,624,000 131,251,000 5,455,000 -35,031,000 -23,013,000 65,274,000 524,000 -33,835,000 60,075,000 -944,000 -53,646,000 53,674,000 -20,105,000 -19,149,000 -534,000 -138,276,000 
      cash and cash equivalents, beginning of period
    		      238,480,000 0 0 0 69,767,000  0                    0 0 22,895,000 0 0 0 59,074,000 0 0 0 120,841,000 0 0 0 70,790,000 0 0 0 61,840,000 0 0 0 2,681,000 0 66,061,000 27,648,000 263,518,000 
      cash and cash equivalents, end of period
    		      193,272,000 155,464,000 -3,168,000 315,000 85,869,000  18,801,000                    -23,292,000 -4,594,000 47,978,000 -12,635,000 -28,203,000 36,080,000 27,653,000 26,146,000 -74,259,000 -13,657,000 120,844,000 -51,624,000 131,251,000 5,455,000 35,759,000 -23,013,000 65,274,000 524,000 28,005,000 60,075,000 1,734,000 -56,324,000 56,355,000 -20,105,000 46,912,000 27,114,000 125,242,000 
      interest on financing liability
    		                                                           
      asset impairment
    		               0    0 0                                       
      interest on milestone right
    		                                                           
      accrued interest on mann group convertible note
    		                                                           
      proceeds from senior convertible notes
    		                                                           
      issuance costs associated with senior convertible notes
    		               0 0 0 -7,268,000                                         
      proceeds from the sale-leaseback transaction
    		                                                           
      issuance costs associated with the sale-leaseback transaction
    		                                                           
      deposit for the sale-leaseback transaction
    		                                                           
      principal payments on mann group convertible note
    		                                                           
      payment on midcap credit facility
    		       -5,000,000                                                    
      payment of midcap credit facility prepayment penalty
    		               0 0                                           
      stock-based compensation expense
    		        4,601,000 5,580,000 3,655,000 2,597,000 3,622,000 4,422,000 2,806,000 3,160,000 3,179,000 3,926,000 1,935,000 1,904,000 1,294,000 2,185,000 1,128,000 891,000 1,640,000 2,673,000 999,000 1,142,000 1,563,000 2,209,000 1,943,000 1,084,000 1,247,000 1,249,000 1,267,000 1,005,000 1,502,000 1,355,000 1,273,000 2,347,000 2,600,000 1,775,000 2,003,000 1,867,000 -4,828,000 40,646,000 10,937,000 13,882,000 15,942,000 10,173,000 5,189,000 3,522,000 3,819,000 3,073,000 2,878,000 3,181,000 2,708,000  5,460,000 
      interest expense on mann group convertible note
    		        56,000 54,000 55,000                                                 
      interest expense on financing liability
    		        -4,847,000 2,449,000 2,424,000 2,425,000 2,313,000 2,443,000 2,371,000                                             
      proceeds from maturity of debt securities
    		        23,525,000 46,980,000 22,103,000 24,756,000 29,277,000 26,769,000 26,538,000                                             
      payment on financing liability
    		        -22,000 -43,000 -72,000 -16,000 1,397,000                                               
      net issuance of common stock associated with stock options and restricted stock units
    		          52,000                                                 
      depreciation, amortization and accretion
    		               1,220,000 1,324,000 1,016,000 655,000 510,000 534,000 567,000 538,000 565,000 -332,000 372,000 367,000 368,000 1,030,000 753,000 706,000 821,000 920,000 879,000 908,000                         
      interest expense on mann group promissory notes
    		                82,000 370,000 1,028,000                                         
      (gain) loss on foreign currency translation
    		               -1,564,000 -2,068,000         1,247,000 -1,935,000 -1,361,000 -728,000                               
      in-process research and development
    		                                                           
      accrued interest on mann group promissory notes
    		               0 0                                           
      proceeds from sale of treasury bills
    		                   0 0 0 20,000,000 -2,000                                    
      acquisition of in-process research and development, net of cash acquired
    		                                                           
      issuance costs associated with at the market offering
    		                   -150,000 -37,000                                       
      proceeds from market price stock purchase plan and from employee stock purchase plan
    		                                                           
      issuance of common stock from the exercise of warrants
    		                   0 0                                       
      proceeds from midcap credit facility
    		                       0                                    
      proceeds from ppp loan
    		                                                           
      proceeds from the senior convertible notes
    		               0 0 0 230,000,000                                         
      principal payments on mann group promissory notes
    		               0 0                                           
      payment of midcap credit facility
    		               0 0                                           
      net increase in cash and cash equivalents and restricted cash
    		              -56,941,000 72,444,000 -10,782,000 -185,469,000 180,828,000 14,449,000 -10,824,000 24,354,000 8,962,000       -528,000 -21,122,000                             
      cash and cash equivalents and restricted cash, beginning of period
    		              124,184,000 0 0 0 67,163,000 0 0 0 30,222,000 0 0 0 71,684,000 0 0 0 48,355,000                             
      cash and cash equivalents and restricted cash, end of period
    		              67,243,000 72,444,000 -10,782,000 -185,469,000 247,991,000 14,449,000 -10,824,000 24,354,000 39,184,000 -267,000 17,205,000 -21,773,000 35,057,000 60,711,000 -15,732,000 -528,000 27,233,000                             
      interest on milestone payment
    		                0                                           
      interest expense on mann group promissory note
    		                                                           
      gain on foreign currency translation
    		            -1,799,000 -4,503,000 -1,983,000    -3,838,000 4,008,000 3,927,000 1,867,000 -1,796,000 2,582,000                                    
      payment-in-kind interest on mann group promissory note
    		                                                           
      accrued interest on mann group mann group promissory note
    		                                                           
      customer deposits
    		            -1,563,000 -5,491,000 2,104,000                                             
      purchase of debt securities
    		            -1,658,000 -12,482,000 -55,988,000  -96,486,000 -108,478,000 -30,442,000                                         
      payment of employment taxes related to vested restricted stock units and exercise of stock options
    		            -192,000 -377,000 129,000 240,000 -590,000 -545,000 397,000 332,000 102,000                                       
      principal payments on mann group mann group promissory note
    		                                                           
      reclassification of investments from long-term to current
    		            19,854,000 37,423,000 14,813,000                                             
      payments on debt and interest through common stock issuance
    		            99,000                                               
      modification of operating leases
    		            0                                               
      addition of right-of-use asset
    		            0                                               
      non-cash construction in progress and property and equipment
    		            517,000 533,000 383,000  -1,029,000 1,059,000 124,000    32,000                558,000  -431,000 -471,000 1,094,000 -2,041,000 844,000 1,265,000 1,700,000 -4,667,000 918,000 742,000 3,863,000 1,165,000 564,000 1,422,000 921,000 69,000 4,371,000 7,281,000  
      common stock issuance to settle employee stock purchase plan liability
    		            873,000 0 740,000    390,000 0 366,000 0 318,000 0 339,000 0 317,000                                 
      contingent milestone liability
    		            0                                               
      premium on mann group convertible note
    		                0                                           
      forgiveness of ppp loan
    		                                                           
      interest expense on promissory notes
    		             86,000 116,000     1,296,000 1,316,000 1,279,000 1,257,000 1,195,000                                    
      ut owned property and equipment
    		                                                           
      payment on mann group convertible note through issuance of common stock
    		                2,000 0 9,573,000                                         
      payment of 2024 convertible notes through common stock issuance
    		                  5,000,000                                         
      reclassification of the ppp loan from current to long-term
    		                  609,000                                         
      payment of mann group convertible note interest through issuance of common stock
    		                0 0 427,000                                         
      payment of interest on 2024 convertible notes through common stock issuance
    		                  143,000                                         
      amortization of financing liability
    		                                                           
      proceeds from sale of debt securities
    		                                                           
      proceeds from market price stock purchase
    		                0                                           
      interest paid in cash, net of amounts capitalized
    		                3,818,000 5,623,000 1,094,000 697,000 1,041,000 935,000 885,000     864,000 1,035,000 0 1,860,000 1,355,000 2,232,000 1,591,000 2,550,000  2,590,000 1,895,000 2,713,000  4,795,000 1,895,000 4,749,000  4,444,000 618,000 4,678,000  2,856,000 2,143,000 2,863,000  2,875,000 2,156,000 2,595,000 2,156,000    
      right-of-use asset modification
    		                                                           
      addition of operating lease liability
    		                                                           
      operating lease liability modification
    		                                                           
      payment of 2024 convertible notes through issuance of common stock
    		                0                                           
      issuance of common stock under employee stock purchase plan
    		                700,000                                           
      payment of interest on 2024 convertible notes through issuance of common stock
    		                0                                           
      payment of principal on senior convertible notes through issuance of common stock
    		                                                           
      receivable from at-the-market offering
    		                                                           
      payment-in-kind interest on promissory notes
    		                       0                                    
      gain on extinguishment of debt
    		                                                           
      loss on warrant transactions
    		                                                           
      purchase of treasury bills
    		                       -91,000                                    
      purchase of limited liability company ownership interest
    		                       0                                    
      proceeds from at the market offering
    		                   8,311,000 2,575,000                                       
      proceeds from paycheck protection program loan
    		                   0 0                                       
      proceeds from promissory notes
    		                       0                                    
      principal payments on promissory notes
    		                                                           
      principal payments on senior convertible notes
    		                                                           
      principal payments on facility financing obligation
    		                       0 -4,420,000   -3,000,000    0 0                           
      issuance cost associated with midcap credit facility
    		                       0                                    
      repurchase of warrants
    		                                                           
      issuance cost associated with promissory notes
    		                                                           
      issuance of common stock for acquisition of in-process research and development
    		                                                           
      payment on promissory notes through issuance of common stock
    		                                                           
      payment on interest of promissory notes through issuance of common stock
    		                                                           
      payment of senior convertible notes through common stock issuance
    		                       0                                    
      payment of interest on senior convertible notes through common stock issuance
    		                   0 144,000 0 144,000 0 537,000 4,000 534,000                                 
      issuance of warrants associated with midcap credit facility
    		                                                           
      receivable from at the market offering
    		                   -348,000 104,000                                       
      addition of right-of-use assets upon adoption of new lease guidance
    		                       0 0                                   
      payment of facility obligation through common stock issuance
    		                       0                                    
      accrued interest on promissory notes
    		                                                           
      payment of principal on senior convertible notes through common stock issuance
    		                    0                                       
      impairment of commitment asset
    		                      1,521,000                                     
      exercise of stock options
    		                      8,000 74,000 32,000                                   
      payment of employment taxes related to vested restricted stock units
    		                      -325,000      0 -103,000 -81,000 -17,000 -22,000 -13,000 -75,000 -4,000 -158,000 0 -3,000 -25,000 -1,015,000 -56,000 -762,000 -64,000 -26,721,000 -90,000 -33,000 -2,706,000 -1,647,000 -21,000 -427,000 -19,000 -482,000 -8,000 -397,000 -22,000 -26,000 -43,000  
      (gain) loss on extinguishment of debt
    		                       0                                    
      gain on sale, abandonment/disposal or impairment of property and equipment
    		                                                           
      proceeds from sale of property and equipment
    		                           110,000    0 0   0 0 0 17,000 4,000            4,000 0 41,000 32,000 30,000    
      issuance cost associated with mann group promissory notes
    		                                                           
      proceeds from public offering
    		                                                           
      proceeds from direct placement
    		                                    0                       
      issuance cost associated with public offering
    		                                                           
      issuance cost associated with direct placement
    		                           0 0                               
      right-of-use and other assets
    		                        0 -16,000 -340,000                                 
      accrued interest - promissory notes
    		                                                           
      proceeds of senior convertible notes
    		                                                           
      payment of senior convertible notes
    		                                                           
      proceeds from direct placement of common stock
    		                           0 0                               
      proceeds from executive stock purchase plan
    		                                                           
      proceeds from issuance of common stock pursuant to at-the-market offering
    		                                                           
      issuance cost associated with in at-the-market offering
    		                                                           
      net cash (used) provided by financing activities
    		                        65,495,000                                   
      net decrease in cash and cash equivalents and restricted cash
    		                        17,205,000 -21,773,000 -36,627,000                                 
      property and equipment in progress in accounts payable
    		                        -587,000 544,000 246,000                                 
      principal and interest payments on promissory notes through common stock issuance
    		                                                           
      payment of note obligations through common stock issuance
    		                              9,407,000                             
      accrued but unpaid debt issuance costs
    		                            -10,000                               
      interest on note payable to related party
    		                         1,163,000 1,134,000 1,143,000 1,126,000 1,097,000 1,122,000                             
      operating lease payments
    		                         -304,000 -395,000                                 
      purchase of short-term investments
    		                         -145,000 -24,764,000                                 
      proceeds from issuance of common stock pursuant to at-the-market issuance
    		                           1,270,000 185,000 0 634,000                             
      issuance cost of at-the-market transactions
    		                            -8,000 0 -25,000                             
      payment of note payable to related party through common stock issuance
    		                            0 0 8,160,000                             
      restricted stock unit award
    		                          105,000                                 
      accrued but unpaid debt issuance costs related to note payable to related party
    		                              75,000                             
      addition of right-of-use assets
    		                          5,192,000                                 
      change in fair value of warrant liability
    		                               0 1,288,000 -147,000 -6,629,000                         
      interest incurred through borrowings under sanofi loan facility
    		                                   353,000 1,521,000 1,436,000 1,168,000                     
      series a warrant issuance cost
    		                                                           
      (gain) loss on sale, abandonment/disposal or impairment of property and equipment
    		                           -104,000                     0    0 -41,000 -32,000     
      gain on purchase commitments
    		                                                           
      receivable from sanofi
    		                               0 0 0 30,557,000                         
      deferred costs from commercial product sales
    		                               138,000 -43,000 -28,000 -163,000 -30,000                        
      deferred costs from collaboration
    		                                   0                        
      deferred payments from collaboration
    		                             2,112,000 -63,000 -63,000 -62,000 -62,000 -63,000                         
      deferred sales from collaboration
    		                                   0 -26,882,000                       
      loss on purchase commitments
    		                                                           
      net proceeds from sale of asset held for sale
    		                               0 0                           
      proceeds from public offering — common stock
    		                                                           
      proceeds from issuance of common stock
    		                                   121,000 38,000 267,000 467,000                     
      borrowings on note payable to related party
    		                                                           
      issuance costs of at-the-market transactions
    		                                                           
      payment of note obligations and interest through issuance of common stock
    		                                                           
      payment of note payable to related party through issuance of common stock
    		                                                           
      capitalization of interest on note payable to related party
    		                                                   2,343,000 0       
      reclassification of deferred payments from collaboration to sanofi loan facility and loss share obligation
    		                                   461,000 -290,000                       
      reclassification of property and equipment to asset held for sale
    		                                                           
      reclassification of warrant liability to additional paid-in capital
    		                               -13,000                            
      deferred payments from collaborations
    		                                                           
      loss on sale, abandonment/disposal or impairment of property and equipment
    		                                                           
      payment of note obligations through common stock issuance, net of issuance costs
    		                                                           
      loss on foreign currency translation
    		                              2,984,000  3,685,000 6,847,000 1,545,000                         
      interest on note payable to principal stockholder
    		                               1,174,000 1,173,000 721,000 714,000                         
      (gain) loss on purchase commitments
    		                                                           
      receivable from collaboration
    		                                                           
      milestone rights liability and other liabilities
    		                                                           
      proceeds from issuance of common stock under tel aviv stock exchange
    		                                                           
      issuance cost associated with the tel aviv stock exchange
    		                                                           
      exercise of warrants for common stock
    		                                              1,938,000 44,977,000 20,862,000           
      payment of debt issuance costs on senior convertible notes
    		                                                           
      borrowings on note payable to principal stockholder
    		                               0 0                           
      capitalization of interest on note payable to principal stockholder
    		                               0 0                           
      gain on disposal of property and equipment
    		                                0                           
      warrant issuance cost
    		                                                           
      net decrease in cash and cash equivalents
    		                                                           
      repayment of facility financing obligation through issuance of common stock
    		                                0                           
      deferred revenue—net
    		                                                           
      reclassification of deferred costs from loss on purchase commitment to deferred costs from collaboration
    		                                                           
      deferred revenue - net
    		                                  -1,575,000                         
      net proceeds from sale of property and equipment
    		                                  16,651,000                         
      cost incurred for construction in progress included in accounts payable and accrued liabilities
    		                                                           
      series a warrant issuance costs
    		                                                           
      write-off of tranche b commitment asset
    		                                                           
      write-off of derivative liability
    		                                           0 0               
      receivables from collaboration
    		                                     144,000 -121,000 1,656,000 3,069,000 -466,000 46,154,000                 
      proceeds from direct placement of common stock and warrants
    		                                                           
      issuance costs associated with direct placement
    		                                   0                        
      payment of notes payable to deerfield
    		                                                           
      issuance costs associated with the tel aviv stock exchange
    		                                                           
      payment of 2015 notes
    		                                       0                    
      payment of debt issuance costs on 2018 notes
    		                                       0                    
      proceeds from issuance of facility financing obligation and milestone rights
    		                                                           
      proceeds from issuance of tranche b of the facility financing obligation
    		                                           0 0               
      interest paid in cash, net of amounts capitalized to construction in progress
    		                                                           
      payment of 2015 notes and interest through issuance of common stock
    		                                       0                    
      issuance of common stock pursuant to debt conversion by deerfield
    		                                                           
      depreciation and accretion
    		                                    1,039,000 1,035,000 1,023,000 3,182,000 3,470,000 3,636,000 2,988,000 3,001,000 2,960,000 3,220,000 9,394,000 3,948,000 3,441,000 3,320,000 3,348,000         
      loss on disposal of property and equipment
    		                                        15,000                   
      interest on note payable to our principal stockholder
    		                                                           
      loss on foreign currency exchange
    		                                    1,012,000 -341,000 2,364,000                     
      warrant fair value adjustment
    		                                    -13,185,000                       
      series a warrant issuance costs included in financing
    		                                                           
      deferred payment from collaboration
    		                                                           
      principal payments on notes payable to deerfield
    		                                                           
      issuance costs of at-the-market issuance
    		                                                           
      adjustments to reconcile net income to net cash from (used) in operating activities:
    		                                                           
      changes in assets and liabilities:
    		                                                           
      purchase commitment loss - current
    		                                                           
      non-current purchase commitment loss
    		                                                           
      other liabilities
    		                                      721,000 734,000 728,000 722,000 743,000 729,000 751,000 721,000 714,000             
      issuance costs associated with the direct placement
    		                                                           
      proceeds from issuance of common stock pursuant to atm issuance
    		                                        12,486,000                   
      deferred product costs from collaboration
    		                                       0 -2,708,000 -4,580,000 -6,251,000                 
      deferred product sales from collaboration
    		                                      177,000 29,000 4,070,000 5,918,000 7,050,000                 
      write-off tranche b commitment asset
    		                                                           
      foreign exchange loss
    		                                                           
      payment of 3.75% senior convertible notes due 2013
    		                                                           
      proceeds from issuance of facility financing obligation & milestone rights
    		                                           0    40,000,000            
      facility financing obligation & milestone rights issuance costs
    		                                               0            
      reduction of principal on note payable to principal stockholder upon issuance of common stock and exercise of warrants
    		                                                           
      interest paid through borrowings under sanofi loan facility
    		                                                           
      write off of derivative liability
    		                                                           
      income from sale of intellectual property
    		                                                           
      interest expense related to milestone payment
    		                                                           
      deferred up-front payment from collaboration agreement
    		                                                           
      proceeds from sale of intellectual property
    		                                                           
      proceeds from issuance of common stock and warrants
    		                                                           
      issuance costs of atm
    		                                                           
      issuance of common stock pursuant to conversion of facility financing obligation
    		                                            0 7,500,000 86,000,000             
      reclassification of share-based awards to liability
    		                                            42,889,000               
      tranche b commitment asset
    		                                            0 -1,168,000 2,921,000             
      reclassification of deferred payments from collaboration to sanofi loan facility
    		                                                           
      issuance of common stock and warrants, net of issuance costs
    		                                         6,652,000 6,168,000 1,547,000 17,951,000 19,159,000 1,463,000 49,933,000 297,000 2,113,000 78,000  0 -80,518,000 80,598,000     
      issuance of common stock for notes receivable
    		                                                           
      adjustments to reconcile net income to net cash provide by (used in) operating activities:
    		                                                           
      fair value of forward purchase contract
    		                                                   13,248,000 0 -10,306,000 -1,705,000     
      common shares issued pursuant to litigation settlement
    		                                                           
      commitment to deliver common shares pursuant to litigation settlement
    		                                                           
      state research and development credit exchange receivable
    		                                           752,000 -600,000 -83,000 -82,000 224,000 399,000 -79,000 -78,000 -20,000 -85,000 -93,000 -92,000 678,000 -100,000 1,325,000 -310,000 
      deferred cash payments from collaboration
    		                                                           
      payment of 2013 notes
    		                                                           
      payment of milestone rights
    		                                                           
      borrowings on notes payable to principal stockholder
    		                                                           
      forward purchase contracts contribution to additional paid-in capital
    		                                                           
      reclassification of forward purchase contracts to additional paid-in capital
    		                                                           
      reclassification of collaboration loan facility obligation
    		                                                           
      stock expense for shares issued pursuant to research agreement
    		                                                           
      accrued interest on investments, net of amortization of discounts
    		                                                         -12,000  
      goodwill impairment
    		                                                           
      litigation settlement in stock
    		                                                           
      purchase of marketable securities
    		                                                         -2,000,000 -15,901,000 
      sales and maturities of marketable securities
    		                                                       0    
      collection of series c convertible preferred stock subscriptions receivable
    		                                                           
      issuance of series b convertible preferred stock for cash
    		                                                           
      cash received for common stock to be issued
    		                                                           
      repurchase of common stock
    		                                                           
      put shares sold to majority stockholder
    		                                                           
      borrowings under lines of credit
    		                                                           
      proceeds from notes receivables
    		                                                           
      principal payments on notes payable to principal stockholder
    		                                                           
      borrowings on notes payable
    		                                                           
      principal payments on notes payable
    		                                                           
      cash paid for income taxes
    		                                                           
      accretion on redeemable convertible preferred stock
    		                                                           
      issuance of common stock upon conversion of notes payable
    		                                                           
      increase in additional paid-in capital resulting from merger
    		                                                           
      issuance of put option by stockholder
    		                                                           
      put option redemption by stockholder
    		                                                           
      issuance of series c convertible preferred stock subscriptions
    		                                                           
      issuance of series a redeemable convertible preferred stock
    		                                                           
      conversion of series a redeemable convertible preferred stock
    		                                                           
      forward purchase contract contribution to apic
    		                                                           
      reclassification of forward purchase contract to apic
    		                                                           
      accrued interest on investments, net of amortization of premiums
    		                                                           
      principal payments on notes payable to our principal stockholder
    		                                                           
      borrowings on notes payable to related party
    		                                                    5,000,000 0 6,250,000     
      principal payments on notes payable to related party
    		                                                           
      cancellation of principal on note payable to related party
    		                                                       0 11,116,000   
      issuance of common stock and warrants for cash
    		                                                           
      borrowings on notes payable from related party
    		                                                           
      reduction of principal on note payable to related party upon issuance of common stock and warrants
    		                                                           
      reduction of principal on note payable to related party upon issuance of common stock
    		                                                           
      forward purchase contract contribution to additional paid-in capital
    		                                                    0       
      reclassification of forward purchase contract to additional paid-in capital
    		                                                    0       
      fair value adjustment of warrant liability
    		                                                     -2,993,000 284,000     
      warrant liability
    		                                                     1,000 7,631,000     
      issuance of common stock and warrants
    		                                                       397,000 9,746,000   
      sales/ maturities of marketable securities
    		                                                        3,828,000   
      stock—based compensation expense
    		                                                         5,836,000  
      in—process research and development
    		                                                           
      discount on stockholder notes below market rate
    		                                                           
      non—cash compensation expense of officer resulting from stockholder contribution
    		                                                           
      accrued interest expense on notes payable to stockholders
    		                                                           
      non—cash interest expense
    		                                                           
      accrued interest on notes receivable
    		                                                           
      loss on available—for—sale securities
    		                                                           
      sales of marketable securities
    		                                                         17,800,000 15,350,000 
      deposit for purchase related to pfizer agreement
    		                                                         -10,000,000  
      borrowings on notes payable from principal stockholder
    		                                                         60,000,000  
      increase in additional paid—in capital resulting from merger
    		                                                           
      loss on sale and abandonment/disposal of property and equipment
    		                                                           
      non-cash compensation expense of officer resulting from stockholder contribution
    		                                                           
      non-cash interest expense
    		                                                           
      proceeds from notes receivable
    		                                                           
      noncash construction in progress
    		                                                           
      noncash transfer from fixed assets to other current assets
    		                                                           
      (gain)/loss on sale and abandonment/disposal of property and equipment
    		                                                           
      accrued interest on notes
    		                                                           
      payment of deferred compensation
    		                                                           
      restricted cash
    		                                                           
      notes receivable by stockholder issued to officers
    		                                                           
      loss/(gain) on sale and abandonment/disposal of property and equipment
    		                                                           
      state r&d credit exchange receivable
    		                                                           
      issuance of common stock for cash
    		                                                           
      payable to stockholder
    		                                                           
      net (decrease)/increase in cash and cash equivalents
    		                                                           
      non-cash compensation to officers
    		                                                           
      stock issued for services
    		                                                           
      notes receivable by stockholder to officers
    		                                                           
      conversion of series b convertible preferred stock
    		                                                           
      conversion of series c convertible preferred stock
    		                                                           
    The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.